The prevalence of mucus plugging in severe eosinophilic asthma and its relationship to clinical efficacy of anti–IL-5R treatment

Andrew P. Hearn; Michelle S. Mak; Irilda Budaj; N. Qurashi; O. Snell; Jaideep Dhariwal; Alexanda M. Nanzer; David J. Jackson

doi:10.1016/j.jaip.2021.12.024

The prevalence of mucus plugging in severe eosinophilic asthma and its relationship to clinical efficacy of anti–IL-5R treatment

Andrew P. Hearn, Michelle S. Mak, Irilda Budaj, N. Qurashi, O. Snell, Jaideep Dhariwal, Alexanda M. Nanzer, David J. Jackson^*

^*Corresponding author for this work

Peter Gorer Department of Immunobiology

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Original language	English
Pages (from-to)	1102-1103.e1
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	10
Issue number	4
Early online date	6 Apr 2022
DOIs	https://doi.org/10.1016/j.jaip.2021.12.024
Publication status	Published - Apr 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jaip.2021.12.024

Cite this

@article{343afc9258134cf2a1ad1ea60a1bfdb7,

title = "The prevalence of mucus plugging in severe eosinophilic asthma and its relationship to clinical efficacy of anti–IL-5R treatment",

author = "Hearn, {Andrew P.} and Mak, {Michelle S.} and Irilda Budaj and N. Qurashi and O. Snell and Jaideep Dhariwal and Nanzer, {Alexanda M.} and Jackson, {David J.}",

note = "Funding Information: Conflicts of interest: D. J. Jackson reports advisory board and speaker fees and congress travel support from GlaxoSmithKline, Astrazeneca, Chiesi, Napp, and Teva Pharmaceuticals. J. Dhariwal reports congress support from Sanofi. A. M. Nanzer reports speaker fees from Astrazeneca and congress travel support from Napp. The rest of the authors declare that they have no relevant conflicts of interest.",

year = "2022",

month = apr,

doi = "10.1016/j.jaip.2021.12.024",

language = "English",

volume = "10",

pages = "1102--1103.e1",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - The prevalence of mucus plugging in severe eosinophilic asthma and its relationship to clinical efficacy of anti–IL-5R treatment

AU - Hearn, Andrew P.

AU - Mak, Michelle S.

AU - Budaj, Irilda

AU - Qurashi, N.

AU - Snell, O.

AU - Dhariwal, Jaideep

AU - Nanzer, Alexanda M.

AU - Jackson, David J.

N1 - Funding Information: Conflicts of interest: D. J. Jackson reports advisory board and speaker fees and congress travel support from GlaxoSmithKline, Astrazeneca, Chiesi, Napp, and Teva Pharmaceuticals. J. Dhariwal reports congress support from Sanofi. A. M. Nanzer reports speaker fees from Astrazeneca and congress travel support from Napp. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2022/4

Y1 - 2022/4

UR - http://www.scopus.com/inward/record.url?scp=85123018922&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2021.12.024

DO - 10.1016/j.jaip.2021.12.024

M3 - Article

AN - SCOPUS:85123018922

SN - 2213-2198

VL - 10

SP - 1102-1103.e1

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 4

ER -

The prevalence of mucus plugging in severe eosinophilic asthma and its relationship to clinical efficacy of anti–IL-5R treatment

UN SDGs

Access to Document

Other files and links

Cite this